Pioneering the Future of Clinical Research With Clinical Biostatistics

IDDI — in partnership with Bristol Myers Squibb, the EORTC, the UCL, the University Hospital and Cancer Center of Lyon, and with the financial support of the Walloon Region, Biowin — developed Generalized Pairwise Comparisons (GPC), a new statistical methodology that combines statistical soundness with the inclusion of patient preferences to pave the way for personalized medicine. After investing in the project, IDDI launched One2Treat in July 2023, a company whose mission is to develop methods and advanced software that enable a holistic evaluation of treatment effects by integrating all key patient-relevant outcomes into a single comprehensive assessment of the Net Treatment Benefit. 

In 2017, IDDI partnered with Biowin, the Walloon cluster of biotechnology, to analytically and clinically validate a CE-marked in vitro diagnostic kit based on a DNA methylation signature predicting the benefit from neoadjuvant anthracycline/taxane chemotherapy in previously untreated, non-metastatic, primary triple negative breast cancer patients.

IDDI: 

• Designed, set up, analyzed, and reported the retrospective study 
• Designed the prospective 
• Statistically supported for signature fine-tuning and kit analytical validation 

The BRAVO project was granted by EuroTransBio to IDDI in collaboration with Pamgene, VUMC, and I-Biostat.

IDDI, with the financial support of the Walloon Region, Biowin, developed a statistical software for Statistical Monitoring Applied to Research Trials (SMART) to detect heterogeneity of data across investigational centers and to create a quality label for clinical trial data. After investing in this project for over a decade, IDDI launched CluePoints in early 2012, offering a unique Central Statistical Monitoring tool.